Literature DB >> 7670118

Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.

L M Faber1, S A van Luxemburg-Heijs, W F Veenhof, R Willemze, J H Falkenburg.   

Abstract

HLA-identical bone marrow transplantation (BMT) is associated with both graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) reactivity. Different T-cell subsets from the bone marrow (BM) graft may be responsible for GVHD and GVL reactivity after BMT. In the etiology of GVHD, not only CD8+ but also CD4+ donor T lymphocytes may play an important role. Here we report a patient with chronic myeloid leukemia (CML) who was transplanted with the BM from his HLA-genotypically identical sister. After BMT there was complete engraftment, but the patient died because of acute GVHD grade III-IV in complete remission. Cytotoxic T-lymphocyte (CTL) lines were generated after BMT using the irradiated leukemic cells from the patient as stimulator cells and the donor-originated peripheral blood mononuclear cells, procured from the patient after BMT, as responder cells. The generated CTL lines showed specific lysis of the recipient lymphocytes and leukemic cells in a 51Cr release assay. Two types of CTL clones could be established from these CTL lines, both phenotypically CD4+. Clone type I showed male-specific HLA-DQ5-restricted lysis of the recipient lymphocytes, but not of the circulating relatively mature leukemic cells from the patient. This may be explained by the low HLA-DQ5 expression of the more mature CML cells. Clone type II showed HLA-DR2-restricted minor histocompatibility antigen-specific lysis of the recipient lymphocytes and leukemic cells. Both types of CTL clones showed antigen-specific cell-mediated growth inhibition of the recipient clonogenic leukemic precursor cells. These CD4+ CTL clones produced several activating cytokines including tumor necrosis factor alpha, interferon gamma, granulocyte-macrophage colony-stimulating factor (GM-CSF), and macrophage CSF. Our results illustrate that these CD4+ CTL clones may have induced GVHD directly by cytolysis and indirectly by activating cytokines. Because both types of CTL clones recognized the recipient leukemic progenitor cells, they may also contribute to GVL reactivity after BMT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670118

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  The clinical implications of mixed lymphocyte reaction with leukemic cells.

Authors:  Hee-Je Kim; Tai-Gyu Kim; Hyun Il Cho; Hoon Han; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

Authors:  E J Claret; E P Alyea; E Orsini; C C Pickett; H Collins; Y Wang; D Neuberg; R J Soiffer; J Ritz
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  Increased Th17/Treg ratio in chronic liver GVHD.

Authors:  F Malard; C Bossard; E Brissot; P Chevallier; T Guillaume; J Delaunay; J-F Mosnier; P Moreau; M Grégoire; B Gaugler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

4.  Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY.

Authors:  Sascha Kretschmann; Stefanie Herda; Heiko Bruns; Josefine Russ; Edith D van der Meijden; Ursula Schlötzer-Schrehardt; Marieke Griffioen; Il-Kang Na; Andreas Mackensen; Anita N Kremer
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

5.  Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.

Authors:  Z Jedlickova; C Schmid; C Koenecke; B Hertenstein; H Baurmann; R Schwerdtfeger; J Tischer; H-J Kolb; M Schleuning
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

Review 6.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

7.  Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences.

Authors:  J Michalek; R H Collins; H P Durrani; P Vaclavkova; L E Ruff; D C Douek; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-16       Impact factor: 11.205

8.  T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.

Authors:  W M Smit; M Rijnbeek; C A van Bergen; W E Fibbe; R Willemze; J H Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice.

Authors:  Yu Yu; Dapeng Wang; Kane Kaosaard; Chen Liu; Jianing Fu; Kelley Haarberg; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Eur J Immunol       Date:  2013-07-04       Impact factor: 5.532

10.  Human HLA-DR transgenes protect mice from fatal virus-induced encephalomyelitis and chronic demyelination.

Authors:  Moses Rodriguez; Laurie Zoecklein; Jason G Kerkvliet; Kevin D Pavelko; Louisa Papke; Charles L Howe; Larry R Pease; Chella David
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.